Table 2 The baseline clinical characteristics of TCGA nccRCC patients (n = 274).
Characteristics | Abundance of CD8T_cluster3_cells | p value | Abundance of sarRCC_cells | p value | Abundance of chr_Macrophages | p value | Consensus cluster | p value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Low (n = 137) | High (n = 137) | Low (n = 137) | High (n = 137) | Low (n = 137) | High (n = 137) | 1 (n = 145) | 2 (n = 69) | 3 (n = 60) | |||||
Age | 0.223 | 0.010 | 0.190 | 0.620 | |||||||||
<60 | 44 | 54 | 39 | 59 | 44 | 54 | 51 | 23 | 24 | ||||
≥60 | 91 | 82 | 97 | 76 | 92 | 81 | 93 | 46 | 34 | ||||
NA | 2 | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 2 | ||||
Gender | 0.642 | 0.729 | 0.879 | 0.305 | |||||||||
Female | 40 | 36 | 39 | 37 | 38 | 38 | 36 | 24 | 16 | ||||
Male | 96 | 98 | 95 | 99 | 99 | 95 | 107 | 44 | 43 | ||||
NA | 1 | 3 | 3 | 1 | 0 | 4 | 2 | 1 | 1 | ||||
AJCC stage | <0.001 | 0.005 | <0.001 | <0.001 | |||||||||
I–II | 131 | 100 | 124 | 107 | 137 | 94 | 145 | 69 | 18 | ||||
III–IV | 6 | 37 | 13 | 30 | 0 | 43 | 0 | 0 | 42 | ||||
TNM stage | <0.001 | 0.010 | <0.001 | <0.001 | |||||||||
I–II | 131 | 104 | 125 | 110 | 137 | 98 | 145 | 69 | 22 | ||||
III–IV | 6 | 33 | 12 | 27 | 0 | 39 | 0 | 0 | 38 | ||||
Overall survival | 0.009 | 0.020 | 0.009 | 0.033 | |||||||||
− | 133 | 121 | 132 | 122 | 133 | 121 | 137 | 66 | 51 | ||||
+ | 4 | 16 | 5 | 15 | 4 | 16 | 8 | 3 | 9 | ||||
Progression-free survival | |||||||||||||
− | 122 | 118 | 0.464 | 122 | 118 | <0.001 | 125 | 115 | 0.067 | 129 | 62 | 49 | 0.284 |
+ | 15 | 19 | 15 | 119 | 12 | 22 | 16 | 7 | 11 | ||||
